Opinion
Video
Outcomes and Adoption of PPAR Agonists in PBC
Key Takeaways
- PBC involves autoimmune-mediated destruction of intrahepatic bile ducts by autoreactive T lymphocytes, leading to cholestasis.
- Accumulation of toxic bile acids due to cholestasis causes hepatocellular damage and inflammation.
The panel of experts addresses potential challenges in the adoption of peroxisome proliferator-activated receptor (PPAR) agonists for primary biliary cholangitis (PBC), including barriers to access, patient selection, and long-term treatment considerations.
Video content above is prompted by the following:
- What could be some potential challenges with the adoption of PPAR agonists for PBC?
Related Videos
Related Content
